Tracer library / [225Ac]Ac-Macropa-PEG4-YS5
[225Ac]Ac-Macropa-PEG4-YS5
Also written as [Ac-225]Macropa-PEG4-YS5; Ac-225-Macropa-PEG4-YS5
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 3
What it is
- Compound class
- Macropa-conjugated anti-CD46 monoclonal antibody (radioimmunoconjugate) with PEG4 linker
- Target / mechanism
- CD46-targeted alpha therapy using antibody YS5 PMID 38389832
- Clinical application
- Targeted alpha particle radioimmunotherapy for metastatic castration-resistant prostate cancer, including PSMA-negative disease, via CD46 targeting PMID 39945595
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | 99.5% | Macropa-PEG4-YS5 | 39945595 2025 Clin Cancer Res The alpha-particle therapy agent [225Ac]Macropa-PEG4-YS5 was prepared according to the previously reported protocol (28). - with an isolated yield of 0.85 MBq |
| Manual synthesis | — | SPE | >95% | >95% | Macropa-PEG4-YS5 | 38389832 2024 Theranostics A standard one-step process was used for radiolabeling. - we achieved a >95% radiochemical yield when labeling Macropa-PEG0/4/8-YS5 with 225Ac |
| Manual synthesis | — | SPE | 96.97% | ~100% | Macropa-PEG4-YS5 | 38389832 2024 Theranostics The mixture was incubated at 25 oC for 1 h. - 96.97% for PEG4 |
Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-PEG4-YS5, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39945595: 'Macropa-PEG4-YS5'.